Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival.
作者信息
Romberg Neil, Morbach Henner, Lawrence Monica G, Kim Sanghyun, Kang Insoo, Holland Steven M, Milner Joshua D, Meffre Eric
出版信息
J Allergy Clin Immunol. 2013 Jun;131(6):1691-3. doi: 10.1016/j.jaci.2013.01.004. Epub 2013 Feb 10.
Abstract
摘要
相似文献
1
Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival.
J Allergy Clin Immunol. 2013 Jun;131(6):1691-3. doi: 10.1016/j.jaci.2013.01.004. Epub 2013 Feb 10.
2
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Clin Breast Cancer. 2018 Oct;18(5):e1205-e1215. doi: 10.1016/j.clbc.2018.05.006. Epub 2018 May 26.
3
Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Leuk Lymphoma. 2017 Apr;58(4):969-978. doi: 10.1080/10428194.2016.1219903. Epub 2016 Aug 11.
4
PD-L1 up-regulation restrains Th17 cell differentiation in loss- and gain-of-function patients.
J Exp Med. 2017 Sep 4;214(9):2523-2533. doi: 10.1084/jem.20161427. Epub 2017 Jul 14.
5
LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
J Exp Clin Cancer Res. 2020 Sep 5;39(1):179. doi: 10.1186/s13046-020-01687-8.
6
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Cancer Biol Ther. 2020 Oct 2;21(10):963-971. doi: 10.1080/15384047.2020.1824479. Epub 2020 Oct 12.
7
Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Mol Carcinog. 2018 Nov;57(11):1588-1598. doi: 10.1002/mc.22881. Epub 2018 Aug 28.
8
The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Breast Cancer Res Treat. 2018 Sep;171(2):273-282. doi: 10.1007/s10549-018-4834-7. Epub 2018 Jun 1.
9
Impaired B-Cell Differentiation in a Patient With Gain-of-Function Mutation.
Front Immunol. 2020 Sep 29;11:557521. doi: 10.3389/fimmu.2020.557521. eCollection 2020.
10
IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Sci Rep. 2017 Dec 19;7(1):17810. doi: 10.1038/s41598-017-18132-0.
引用本文的文献
1
A Norwegian cohort with STAT1-related disease - further expanding the clinical phenotype.
Front Immunol. 2025 Aug 13;16:1620291. doi: 10.3389/fimmu.2025.1620291. eCollection 2025.
2
Infections in Inborn Errors of STATs.
Pathogens. 2024 Nov 1;13(11):955. doi: 10.3390/pathogens13110955.
3
STAT1 and STAT3 gain of function: clinically heterogenous immune regulatory disorders.
Curr Opin Allergy Clin Immunol. 2024 Dec 1;24(6):440-447. doi: 10.1097/ACI.0000000000001039. Epub 2024 Oct 17.
4
Retrospective identification of the first cord blood-transplanted severe aplastic anemia in a -associated chronic mucocutaneous candidiasis family: case report, review of literature and pathophysiologic background.
Front Immunol. 2024 Jul 24;15:1430938. doi: 10.3389/fimmu.2024.1430938. eCollection 2024.
5
Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
J Clin Immunol. 2024 Apr 5;44(4):85. doi: 10.1007/s10875-024-01684-y.
6
The human Stat1 gain-of-function T385M mutation causes expansion of activated T-follicular helper/T-helper 1-like CD4 T cells and sex-biased autoimmunity in specific pathogen-free mice.
Front Immunol. 2023 May 19;14:1183273. doi: 10.3389/fimmu.2023.1183273. eCollection 2023.
7
JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences.
J Clin Immunol. 2023 Aug;43(6):1326-1359. doi: 10.1007/s10875-023-01483-x. Epub 2023 May 4.
8
Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis.
Front Immunol. 2022 Sep 12;13:983977. doi: 10.3389/fimmu.2022.983977. eCollection 2022.
9
STAT1 coordinates intestinal epithelial cell death during gastrointestinal infection upstream of Caspase-8.
Mucosal Immunol. 2022 Jan;15(1):130-142. doi: 10.1038/s41385-021-00450-2. Epub 2021 Sep 8.
10
STAT1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses.
NPJ Genom Med. 2021 May 14;6(1):34. doi: 10.1038/s41525-021-00196-7.
本文引用的文献
1
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.
Immunity. 2012 Jun 29;36(6):1017-30. doi: 10.1016/j.immuni.2012.03.024. Epub 2012 Jun 21.
2
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
J Exp Med. 2011 Aug 1;208(8):1635-48. doi: 10.1084/jem.20110958. Epub 2011 Jul 4.
3
STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
N Engl J Med. 2011 Jul 7;365(1):54-61. doi: 10.1056/NEJMoa1100102. Epub 2011 Jun 29.
4
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
Nature. 2008 Apr 10;452(7188):773-6. doi: 10.1038/nature06764. Epub 2008 Mar 12.
5
STAT1-induced apoptosis is mediated by caspases 2, 3, and 7.
J Biol Chem. 2004 Feb 6;279(6):4066-74. doi: 10.1074/jbc.M307774200. Epub 2003 Nov 17.
6
Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma.
Leuk Res. 2002 Aug;26(8):745-55. doi: 10.1016/s0145-2126(01)00202-8.
7
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.
Science. 1996 May 3;272(5262):719-22. doi: 10.1126/science.272.5262.719.
Zotero 插件